Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report
Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report
复制标题
DOI：
10.1097/01.bpb.0000194439.75378.ac
复制
发表时间：
2006-05-01
影响因子：
1.1
通讯作者：
Vukicevic, Slobodan
中科院分区：
文献类型：
--
作者：
Anticevic, Darko;Jelic, Mislav;Vukicevic, Slobodan
先天性胫骨假关节仍然是骨科最难治疗的问题之一。在使用重组骨形态发生蛋白(骨形态发生蛋白-7；成骨蛋白-1)之前，本报告中的先天性胫骨假关节患者有12次手术失败。在根治性硬化性胫骨节段切除、Ilizarov固定和应用成骨蛋白-1成骨装置后5个月，先天性胫骨假关节愈合；45个月时，胫骨增大，患者完全负重。
Congenital pseudarthrosis of the tibia remains one of the most difficult orthopaedic problems to treat. Before the use of a recombinant bone morphogenetic protein (bone morphogenetic protein-7; osteogenic protein-1) the patient with congenital pseudarthrosis of the tibia in this report had had 12 unsuccessful surgeries. Five months after radical resection of sclerotic tibial segments, llizarov fixation and administration of osteogenic protein-1 osteogenic device, the congenital pseudarthrosis of the tibia healed; at 45 months the tibia increased in size and the patient was fully weight bearing.